Metropolitan Life Insurance Company (MetLife)’s Century Therapeutics IPSC Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio IPSC Stock Details IPSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,426	Closed	-$7.32K	–	2387
2022 Q4	$7.32K	Hold	1,426	–	–	﹤0.01%	2342
2022 Q3	$14.1K	Hold	1,426	–	–	﹤0.01%	2180
2022 Q2	$12K	Hold	1,426	–	–	﹤0.01%	2275
2022 Q1	$18K	Buy	+1,426	New	+$18.9K	﹤0.01%	2141
2021 Q4	–	Sell	-3,737	Closed	-$94K	–	2807
2021 Q3	$94K	Buy	+3,737	New	+$101K	﹤0.01%	2557

Other funds holding IPSC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s IPSC Position: Q1 2023 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Century Therapeutics (IPSC) in Q1 2023, closing a stake of 1,426 shares — an estimated $7.32K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in IPSC in Q3 2021 and held it in 5 quarters. The position peaked at $94K in Q3 2021. 63 funds tracked by Wall St. Rank hold IPSC as of Q1 2023.

Metropolitan Life Insurance Company (MetLife) reported no remaining Century Therapeutics position as of Q1 2023 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 1,426 Century Therapeutics shares in Q1 2023, an estimated $7.32K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Century Therapeutics in Q3 2021 and held it in 5 quarters.
Metropolitan Life Insurance Company (MetLife)'s Century Therapeutics position peaked at $94K in Q3 2021.
63 funds tracked by Wall St. Rank held Century Therapeutics as of Q1 2023.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q1 2023, filed 15 May 2023.